3-aminolevamisole profile

3-aminolevamisole: RN given for cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3038669
CHEMBL ID	292390
SCHEMBL ID	5129548
MeSH ID	M0146308

Synonym
3-aminolevamisole
CHEMBL292390
3-(2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazol-6-yl)aniline
43081-63-6
meta-aminolevamisole
benzenamine, 3-(2,3,5,6-tetrahydroimidazo(2,1-b)thiazol-6-yl)-
3-mal
60348-13-2
SCHEMBL5129548
IQGVBROUGQZILV-UHFFFAOYSA-N
6-(m-aminophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
3-(2,3,5,6-tetrahydroimidazo[2,1-b]thiazol-6-yl)aniline
DTXSID70962883

Bioassays (9)

Assay ID	Title	Year	Journal	Article
AID136621	Nematocidal against Nematospiroides dubius in mouse was determined at 100 mg/kg peroral dose of compound; ND means no data	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID136622	Nematocidal against Nematospiroides dubius in mouse was determined at 1 mg/kg peroral dose of compound	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID204104	Toxic activity expressed as the percentage against liver fluke in the sheep at 15 mg/kg peroral administration of dose	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID136626	Nematocidal against Nematospiroides dubius in mouse was determined at 50 mg/kg peroral dose of compound; all animals died at this dose	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID136618	Nematocidal against Nematospiroides dubius in mouse was determined at 0.5 mg/kg peroral dose of compound	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID204106	Toxic activity expressed as the percentage against liver fluke in the sheep at 30 mg/kg peroral administration of dose; lethal	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID204107	Toxic activity expressed as the percentage against liver fluke in the sheep at 300 mg/kg peroral administration of dose; ND means no data	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID136627	Nematocidal against Nematospiroides dubius in mouse was determined at 5 mg/kg peroral dose of compound	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
AID136624	Nematocidal against Nematospiroides dubius in mouse was determined at 25 mg/kg peroral dose of compound; ND means no data	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (27.78)	18.7374
1990's	1 (5.56)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	12 (66.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (11.11%)	6.00%
Case Studies	2 (11.11%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (77.78%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
mecamylamine Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	1.97	1	primary aliphatic amine
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	3.47	8	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
n-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide: structure in first source	1.93	1	aminoxyls; dicarboximide; maleimides; pyrrolidines

Condition	Relationship Strength	Studies
Fasciola Infection [description not available]	1.97	1
Infections, Nematode [description not available]	1.97	1
Fascioliasis Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.	1.97	1
Degenerative Diseases, Central Nervous System [description not available]	3.52	1
Autosomal Dominant Juvenile Parkinson Disease [description not available]	3.52	1
Brain Inflammation [description not available]	3.52	1
Autoimmune Diseases of the Nervous System Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME).	3.52	1
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	3.52	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	3.52	1
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	3.52	1
Hepatocellular Carcinoma [description not available]	3.74	2
Cirrhosis, Liver [description not available]	3.33	1
Cancer of Liver [description not available]	3.74	2
Local Neoplasm Recurrence [description not available]	3.33	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	3.74	2
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	3.33	1
Liver Neoplasms Tumors or cancer of the LIVER.	3.74	2
Complication, Postoperative [description not available]	2.9	2
Colorectal Cancer [description not available]	2.9	2
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	2.9	2
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.9	2
Airflow Obstruction, Chronic [description not available]	3.01	2
Lassitude [description not available]	2.6	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	2.6	1
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	3.01	2
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	2.6	1
Cancer of Nasopharynx [description not available]	2.6	1
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.6	1
Centriacinar Emphysema [description not available]	2.6	1
Emphysema A pathological accumulation of air in tissues or organs.	2.6	1
Cancer of Pancreas [description not available]	3.52	4
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	3.52	4
Cancer of Stomach [description not available]	2.6	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.6	1
Capdepont Teeth [description not available]	1.93	1
Brittle Bone Disease [description not available]	1.93	1
Abnormalities, Teeth [description not available]	1.93	1
Osteogenesis Imperfecta COLLAGEN DISEASES characterized by brittle, osteoporotic, and easily fractured bones. It may also present with blue sclerae, loose joints, and imperfect dentin formation. Most types are autosomal dominant and are associated with mutations in COLLAGEN TYPE I.	1.93	1
Granulomas [description not available]	1.93	1
Benign Neoplasms [description not available]	1.93	1
Essential Polyarteritis [description not available]	2.34	2
Facial Neoplasms New abnormal growth of tissue in the FACE.	1.93	1
Granuloma Gangraenescens [description not available]	2.34	2
Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.	1.93	1
Granuloma, Lethal Midline A condition that is characterized by inflammation, ulceration, and perforation of the nose and the PALATE with progressive destruction of midline facial structures. This syndrome can be manifested in several diseases including the nasal type of EXTRANODAL NK-T-CELL LYMPHOMA and GRANULOMATOSIS WITH POLYANGIITIS.	2.34	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1.93	1
Granulomatosis, Wegener's [description not available]	1.93	1
Granulomatosis with Polyangiitis A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.	1.93	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.99	1

3-aminolevamisole

Description

Cross-References

Synonyms (13)

Bioassays (9)

Research

Studies (18)

Market Indicators

Research Demand Index: 11.35

Study Types

3-aminolevamisole

Description

Cross-References

Synonyms (13)

Bioassays (9)

Research

Studies (18)

Market Indicators

Research Demand Index: 11.35

Study Types

Related Drugs (3)

Related Conditions (49)